new BindingDB logo
myBDB logout

15 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27994728 23 Pyrazole Inhibitors of GluN2B NMDA Receptor Subunit.EBI Dart Neuroscience LLC
27061977 8 Benzimidazolone bioisosteres of potent GluN2B selective NMDA receptor antagonists.EBI Institut f£r Pharmazeutische und Medizinische Chemie der Universit£t M£nster
25458498 29 Synthesis, GluN2B affinity and selectivity of benzo[7]annulen-7-amines.EBI Institut f£r Pharmazeutische und Medizinische Chemie der Universit£t M£nster
22366657 39 A novel series of benzimidazole NR2B-selective NMDA receptor antagonists.EBI GlaxoSmithKline R&D
21524576 69 2,6-Disubstituted pyrazines and related analogs as NR2B site antagonists of the NMDA receptor with anti-depressant activity.EBI AstraZeneca Pharmaceuticals
19648007 3 Synthesis and evaluation of novel tricyclic benzo[4.5]cyclohepta[1.2]pyridine derivatives as NMDA/NR2B antagonists.EBI Merck Research Laboratories
17498948 24 Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.EBI Merck Research Laboratories
17249648 64 Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.EBI Merck Research Laboratories
12639561 51 Orally efficacious NR2B-selective NMDA receptor antagonists.EBI Merck Research Laboratories
12519057 22 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity.EBI Merck Research Laboratories
10741546 66 Parallel synthesis of a series of subtype-selective NMDA receptor antagonists.EBI Parke-Davis Pharmaceutical Research
17761421 10 Identification of novel chemical inhibitors for ubiquitin C-terminal hydrolase-L3 by virtual screening.BDB Waseda University
15771420 58 Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4-[(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.BDB Bristol-Myers Squibb Pharmaceutical Research Institute
11881999 123 Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.BDB AstraZeneca